The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

I-MAK Wins: Gilead Loses Appeal on Sofosbuvir Patent in China

The China patent office’s re-examination board has upheld June 2015 rejection of a critical sofosbuvir patent, denying Gilead’s appeal on I-MAK’s winning case. The patent office ruled that the sofosbuvir prodrug did not deserve a patent under the law. This comes as I-MAK just filed a new legal challenge against the sofosbuvir base compound in China  on April 19th, 2017. Freeing sofosbuvir of its unmerited patents in the country would open the door to affo

European regulator amends some Gilead hep C patent claims

In a setback for Gilead Sciences, European regulators decided not to uphold all of its patent claims for the best-selling Sovaldi hepatitis C treatment, a move that could lead to generic versions of the medicine becoming available four years sooner than had been expected. The European Patent Office on Tuesday amended several patent claims that were challenged by Medicins Du Monde, a medical aid charity, which argued that Gilead was abusing the patent sy...

Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition

European Patent Office (EPO) has taken its decision following Doctors of the World - Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent. MdM has filled an opposition on the patent granted to Gilead Sciences for Sofosbuvir (Sovaldi®) on February 10th, 2015. A patent opposition is a legal procedure by means of which the validity of a patent can be challenged because the drug...

All You Need to Know: September’s Crucial Verdict on the Sofosbuvir Patent Saga

The patent also covers the raw materials to make the drugs, which means it would allow the manufacturer to disrupt exports of the raw materials from India. In September, India will witness the first hearing in a crucial court case on the grant of a patent for the anti-hepatitis-C drug sofosbuvir – a drug whose patent was rejected and then approved by the same patent court, albeit by two different officials. A recent report of the international medical cha